Dear Colleagues,

Heart failure (HF) affects about 26 million people worldwide, including 6 million Americans. HF is associated with serious morbidity, mortality, hospital admissions, and burgeoning healthcare costs. The clinical syndromes of HF are broadly divided into two categories: HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). Despite being a syndrome of heterogeneous mechanisms, HFrEF is well investigated, with management guidelines being periodically published by the ACC/AHA and ESC. Referring to these guidelines would help patients tremendously. On the other hand, HFpEF, another syndrome of multiple mechanisms, is less understood; after excluding valvular disorders as potential contributors, fault lies in the diastolic performance of the left ventricular myocardium. As diastolic function is difficult to measure, this entity carries the misnomer of HFpEF instead of diastolic heart failure. EF is not everything, as it is a poor marker of LV systolic function and depends not only on LV contractile function but also on LV preload and afterload. We want to give further insights into “diastolic heart failure”, as there are very few updated reports on this syndrome in terms of mechanisms and management procedures.

Furthermore, there are other entities that are important but that are under-recognized and not fully treated or managed. These include the recognition and appropriate management of cardiac amyloidosis and cardiac sarcoidosis. In addition, many anticancer treatments, despite promising to cure cancers, cause significant cardiac injury. We would like to further discuss this area of cardio-oncology, i.e., how to balance anticancer benefits against cardiac protection, as cardiac injury is a common side effect.

In addition, we shall have discussions on topics that are evolving, but that are not yet well laid out in the literature. We hope to bridge this knowledge gap in the interests of both patients and physicians.

Prof. Dr. Ramdas G. Pai
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• diastolic heart failure
• heart failure in pregnancy
• cardiac amyloidosis
• cardiac sarcoidosis
• cardio-oncology
• echocardiography
• cardiac magnetic resonance imaging